Vcanbio Cell & Gene Engineering Corp., Ltd (SHA:600645)

Market Cap	12.40B
Revenue (ttm)	1.47B
Net Income (ttm)	74.75M
Shares Out	455.90M
EPS (ttm)	0.17
PE Ratio	162.99
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	10,174,915
Average Volume	10,540,858
Open	27.01
Previous Close	26.90
Day's Range	26.90 - 27.84
52-Week Range	18.90 - 30.32
Beta	0.42
RSI	56.11
Earnings Date	Apr 25, 2026

About SHA:600645

Vcanbio Cell & Gene Engineering Corp., Ltd, together with its subsidiaries, engages in the preparation and storage of cell detection tests in the People’s Republic of China. It offers cell test preparation and storage services for umbilical cord blood hematopoietic stem cells, umbilical cord mesenchymal stem cells, placental pluripotent stem cells, immune cells, adipose stem cells, and dental stem cells. The company also provides genetic testing services related to non-invasive prenatal genetic testing during pregnancy, genetic testing for drug...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 1992
• Employees: 2,014
• Stock Exchange: Shanghai Stock Exchange
• Ticker Symbol: 600645

Financial Performance

In 2024, SHA:600645's revenue was 1.59 billion, a decrease of -0.27% compared to the previous year's 1.59 billion. Earnings were 100.35 million, a decrease of -5.73%.